Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
1. A composition comprising a pharmaceutical dosage form having:
a solid core including a salicin source and a combination of melatonin and valerian, the melatonin and valerian being located together within a first acidified polymeric matrix;
an expedited release portion including 5% to 50% of the salicin source, valerian, and melatonin in the pharmaceutical dosage form, the expedited release portion being effective to release substantially all of the salicin source, valerian, and melatonin therein within about 2 hours from placement in a 0.1 N HCl solution; and
a sustained release portion including the remainder of the of the salicin source, valerian and melatonin in the pharmaceutical dosage form, the sustained release portion being effective to release substantially all of the salicin source, valerian, and melatonin therein within about 10 hours from placement in a phosphate buffer with a pH of 6.8.
2. The composition of claim 1 , wherein the first acidified polymeric matrix has a pH of about 1 to about 4.4.
3. The composition of claim 1 , wherein the salicin source is a white willow bark extract that is at least 75% salicin.
4. The composition of claim 1 , wherein the pharmaceutical dosage form is at least one of a compressed tablet, capsule, and multiparticulate-containing oral dosage form.
5. The composition of claim 1 , wherein, in the expedited release portion, the 5% to 50% of the valerian and melatonin in the pharmaceutical dosage form is located within a second acidified polymeric matrix having a pH of about 1 to about 4.4.
6. The composition of claim 1 , wherein the sustained release portion includes a plurality of individual granules that have the remainder of the valerian and melatonin in the pharmaceutical dosage form therein.